# The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection

> **NCT04312997** · PHASE2 · COMPLETED · sponsor: **Pulmotect, Inc.** · enrollment: 101 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** PUL-042 Inhalation Solution
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04312997
- **Lead sponsor:** Pulmotect, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-16
- **Primary completion:** 2021-07-02
- **Final completion:** 2021-07-02
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2023-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04312997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04312997, "The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04312997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*